Close Menu

Emerald BioStructures

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.

The firms achieved a second milestone in their drug discovery pact, which utilizes Emerald's X-ray crystallography platform.

Movers & Shakers

Premium

John Hunt, John McCall, John Mulligan, Lynn Silver

The agreement with NEC, which has purchased an equity stake in the company, is part of its plan to expand beyond its traditional focus on biomarker discovery and diagnostics development to become a "health information company" that can "provide actionable medical information to patients, physicians, and researchers," said an official.

The firms are building on a collaboration from last year, under which they unraveled the first X-ray structure of a DNA aptamer bound to its protein target.

Matt Hancock, the UK health secretary, is calling for the swift rollout of predictive genetic tests, the Guardian reports.

A WHO panel is calling for a global registry of human germline gene-editing projects, according to Stat News.

Vox writes that lab mishaps involving pathogens are quite common.

In Genome Biology this week: analysis of wild and cultivated peach genomes, Hi-C-based pipeline for assembling microbial genomes from metagenomic data, and more.